Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:11 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Initiation of Acid Suppression Therapy Prospective Outcomes for Laryngomalacia
NCT04614974 · Reema Padia · PHASE1/PHASE2 · terminated · last registry update 2025-07-20 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Slow recruitment due to few eligible patients” | – | Registry record, Reema Padia |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against HRH2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-06-29Results posted on the registry: Amy K. Dickey, M.D., Cimetidine + Placebo (NCT05020184)
- 2026-06-23Also stopped (terminated): HonorHealth Research Institute, Botensilimab + Balstilimab (NCT06076837)
- 2026-06-15Results posted on the registry: Northwell Health, Famotidine + Placebo (NCT04724720)
- 2026-06-09Results posted on the registry: Loma Linda University, Dexamethasone (NCT03598426)
- 2026-05-22Results posted on the registry: ZimVie, a drug against HRH2 (NCT02161874)
- 2026-03-18Also stopped (terminated): Centre Oscar Lambret, pursuit of chemotherapy (NCT03301454)
- 2026-03-10Results posted on the registry: The University of Texas Health Science Center, Houston, Pantoprazole + Famotidine (NCT06154226)
- 2026-02-05Also stopped (terminated): National Institute of Allergy and Infectious Diseases (NIAID), elotuzumab + placebo for elotuzumab (NCT04918147)
- 2025-12-05Results posted on the registry: M.D. Anderson Cancer Center, Zofran + Dexamethasone (NCT02473042)
- 2025-12-02Results posted on the registry: National Cancer Institute (NCI), IL-2 (Aldesleukin) + Cyclophosphamide (NCT05035407)
- 2025-12-02Also stopped (terminated): National Cancer Institute (NCI), IL-2 (Aldesleukin) + Cyclophosphamide (NCT05035407)
- 2025-11-21Also stopped (terminated): Restor3D, a drug against HRH2 (NCT02494544)
- 2025-10-08Results posted on the registry: Restor3D, a drug against HRH2 (NCT02494544)
- 2025-09-17Also stopped (terminated): Sanofi, Isatuximab SAR650984 + Acetaminophen (paracetamol) or equivalent (NCT04294459)
- 2025-08-20Results posted on the registry: Ohio State University Comprehensive Cancer Center, Cimetidine + Dexamethasone (NCT04862585)
- 2025-08-08Results posted on the registry: Washington State University, MetFORMIN Oral Solution + Cimetidine 400 MG (NCT05365451)
- 2025-07-17Results posted on the registry: Emory University, Cetirizine + Famotidine (NCT05946551)
- 2025-07-17Also stopped (terminated): Emory University, Cetirizine + Famotidine (NCT05946551)
- 2025-06-03Also stopped (withdrawn): University of Miami, Acetaminophen + Celebrex (NCT05965492)
- 2025-05-06Results posted on the registry: University of Chicago, nab-paclitaxel + Carboplatin (NCT03107182)
- 2025-02-25Results posted on the registry: National Institute of Allergy and Infectious Diseases (NIAID), elotuzumab + placebo for elotuzumab (NCT04918147)
- 2025-02-06Also stopped (terminated): Bristol-Myers Squibb, BMS-986465 + Pegasys (NCT06144697)
- 2025-01-30Phase 3 first posted: The University of Texas Medical Branch, Galveston, Famotidine and 4% topical cromolyn sodium (NCT06801626)
- 2025-01-17Results posted on the registry: Zimmer Biomet, a drug against HRH2 (NCT03073941)
- 2024-11-14Results posted on the registry: Pfizer, Abrocitinib tablet + Abrocitinib Suspension F1 (NCT04903093)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision